Business Wire

MA-HAMAMATSU-PHOTONICS

10.6.2019 05:02:05 CEST | Business Wire | Press release

Share
Hamamatsu Photonics K.K. Has Developed a Novel 3D Fluorescence Scanning Method Called “Zyncscan™“ That Performs an X-Z Plane Scan With a Light-Sheet for Cell-Based Fluorescence Assays in Microplates

Hamamatsu Photonics K.K. (TOKYO:6965) has developed a novel 3D fluorescence scanning method called “Zyncscan™” that performs x-z plane scans using a light-sheet for cell-based fluorescence assays in microplates. This technology provides an x-z plane scan using a light-sheet for a whole 96/384/1536-well microplate, allowing users to obtain 3D fluorescence images of whole wells in xy: 2-3 μm and z: 6-7 μm voxel resolution for ≤ 300 μm thickness from the well bottom within a few minutes per color. This technology also allows for ultra-high level separation of cell fluorescence signals from the background, which makes it possible to obtain fluorescence cell images in the cell culture mediums containing serum and with fluorescent dyes (i.e., no need to wash out fluorescent dyes).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005009/en/

Background of development

In drug discovery and development, there is a rapidly growing need to use more physiologically-relevant in vitro cell culture models. These include primary cells, patient-derived cells, human iPSC-derived disease-modeling cells, co-cultures of different types of cells, and 3D cultures such as spheroids and organoids. To develop and advance phenotypic assays and screenings using these physiologically-relevant cellular models, new types of instruments needed to be developed to facilitate high-throughput fluorescence imaging and measurement of heterogeneous 2D and 3D cell cultures. To meet this need, we have developed ZyncscanTM technology that performs an x-z plane scan utilizing a light-sheet for a microplate.

Features of the cell-based fluorescence assays in microplate using Zyncscan™ technology

1)   High-speed fluorescence cytometry for 2D monolayer heterogeneous cell culture
A single 120-second scan (one color) for a whole 96/384/1536-well microplate enables fluorescence cytometry of all individual cells in all wells.
2) Single spheroid analyses using depth information (diameter of spheroid; ≤ 200 μm)
A single scan (in just a few minutes) for a microplate enables fluorescence images of spheroids (single or multiple spheroids in a well) in all wells in a 96/384/1536-well microplate. From the images, the entire fluorescence intensity, thickness and volume of each individual spheroid are estimated.
3) Fluorescence images in 3D view (≤ 300 μm)
With a single scan (a few minutes) obtain 3D fluorescence images (300 μm from the bottom of a well) of all wells in a plate. The optical resolution of the image is comparable with the 2x objective of a conventional fluorescence microscope in the x- and y-axes and a 10x objective of confocal fluorescence microscope in the z-axis.
4) In-medium / No dye washout measurement
Measure cellular fluorescence in the medium containing serum and with fluorescent dyes (no need to wash out fluorescent dyes), allowing cells to remain healthy throughout the experiment.
 

Future outlook

Hamamatsu Photonics K.K. has been developing a fluorescence instrument for cell-based assays equipped with Zyncscan™ technology, CYTOQUBE™, a Light-Sheet Microplate Cytometer. We plan to initiate validation and application experiments in several research sites in drug discovery and development by early 2020. CYTOQUBE™ is planned to be released by the end of the next fiscal year (September 2020).

We will showcase a prototype of the CYTOQUBE™ (Light-Sheet Microplate Cytometer) at the following conferences.

WPC (World Preclinical Congress)
June 17-20, 2019, Boston, MA, USA

https://www.pharmaweek.com/wpc

CYTO
June 22-26, 2019, Vancouver, BC, Canada

http://www.cytoconference.org/2019/Home.aspx

 

Please visit here for more detailed information.
https://www.hamamatsu.com/all/en/news/featured-products_technologies/2019/20190610000000.html

Hamamatsu Photonics K.K.

Hamamatsu Photonics K.K. is a leading manufacturer of photonics devices. We design, manufacture, and sell optical sensors, light sources, optical components, cameras, photometry systems, and measurement/analysis systems.

Web site

https://www.hamamatsu.com

Contact:

Technical Contacts details Hamamatsu Photonics K.K, System Division Business Promotion Department 812, Joko-cho, Higashi-ku, Hamamatsu City, 431-3196 Japan email: export@sys.hpk.co.jp

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye